Skip to Main Content

Advertisement

Skip Nav Destination

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Mol Cancer Ther (2018) 17 (1_Supplement): LB-B25.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Close Modal

or Create an Account

Close Modal
Close Modal